

Date 11 August 2026
Your Ref
Our Ref 11707

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – OVARIAN CANCER PRESCRIBING

I write in response to your request for information in relation to ovarian cancer prescribing.

Question:

1. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:

Answer:

Paclitaxel in combination with a platinum-based compound	29
Platinum-based therapy alone (cisplatin or carboplatin)	9
Bevacizumab in combination with paclitaxel and carboplatin	5<
Olaparib	21
Olaparib + Bevacizumab	5<
Niraparib	21
Rucaparib	5<
Mirvetuximab soravtansine	5<

Question:

2. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

Answer:

Full Title	Recruited
ACTOv, A multicentre phase II randomised controlled trial to evaluate the efficacy of Adaptive Therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high grade serous or high grade endometrioid ovarian cancer	7
RAMP301, A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)	5<

EPSILOGEN, A Phase Ib, Open-Label Trial of MOv18 IgE in Patients with Solid Tumours that Overexpress Folate Receptor Alpha	5<*
SOPRANO, Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy	0
TroFuse-022, A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (ENGOT-ov84/GOG-3103)	0
TREVI-OC-01, A Randomised, Open-Label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-High and AZD5335 versus Investigator's Choice Chemotherapy in FRα-low Expressing High-Grade Platinum-Resistant Epithelial Ovarian Cancer Patients	5<

*5< Ovarian cancer patients recruited in NHS Lothian

To protect the identity of the individuals involved any figure of 5 or less has not been shown in this response. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive